Strategies To Address Mutagenic Impurities Derived from Degradation in Drug Substances and Drug Products
- 10 June 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 19 (11), 1447-1457
- https://doi.org/10.1021/acs.oprd.5b00091
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Forced degradation studies to assess the stability of drugs and productsTrAC Trends in Analytical Chemistry, 2013
- The Assessment of Impurities for Genotoxic Potential and Subsequent Control in Drug Substance and Drug ProductJournal of Pharmaceutical Sciences, 2013
- Guidelines and pharmacopoeial standards for pharmaceutical impurities: Overview and critical assessmentRegulatory Toxicology and Pharmacology, 2012
- Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspectiveJournal of Pharmaceutical and Biomedical Analysis, 2011
- Overall impact of the regulatory requirements for genotoxic impurities on the drug development processEuropean Journal of Pharmaceutical Sciences, 2011
- Genotoxic Impurities: From Structural Alerts to QualificationOrganic Process Research & Development, 2010
- Risk Assessment of Genotoxic Impurities in Marketed Compounds Administered over a Short-Term Duration: Applications to Oncology Products and Implications for Impurity Control LimitsOrganic Process Research & Development, 2010
- Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and PerspectiveOrganic Process Research & Development, 2010
- Regulation of genotoxic and carcinogenic impurities in drug substances and productsTrAC Trends in Analytical Chemistry, 2006
- The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug developmentRegulatory Toxicology and Pharmacology, 2006